Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02979951
Other study ID # FORTRESS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 2016
Est. completion date December 2030

Study information

Verified date February 2023
Source Infectopharm Arzneimittel GmbH
Contact Thomas Borrmann, Dr.
Email Clinical.Trials@infectopharm.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 2030
Est. primary completion date December 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patients aged = 18 years - Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v. - Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC - Written informed consent of the participant (or person in charge in case of patients incapable of giving consent) Exclusion Criteria: - Previous documentation of the patient in the present study - Patients participating in an interventional clinical trial - Patients with known hypersensitivity to fosfomycin or any of the excipients - Terminally ill patients - Patients with "do not resuscitate order" - Palliative treatment approach - Failure of > 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney - Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS) - Fosfomycin treatment as 4th line treatment or at later stage - Patients with involvement of fungi or mycobacteria in the targeted infection

Study Design


Related Conditions & MeSH terms

  • Abscess
  • Bacteremia
  • Bacterial Infections
  • Bone Diseases
  • Bone Diseases, Infectious
  • Brain Abscess
  • Central Nervous System Bacterial Infections
  • Communicable Diseases
  • Encephalitis
  • Endocarditis
  • Endocarditis, Bacterial
  • Infections
  • Intraabdominal Infections
  • Meningitis
  • Meningitis, Bacterial
  • Osteomyelitis
  • Pneumonia
  • Pneumonia, Bacterial
  • Respiratory Tract Infections
  • Sepsis
  • Skin Diseases
  • Skin Diseases, Bacterial
  • Soft Tissue Infections
  • Urinary Tract Infections

Locations

Country Name City State
Austria Landeskrankenhaus Hall - Tirol Kliniken Hall In Tirol
Austria A.ö. Bezirkskrankenhaus Reutte
Austria Klinikum Wels-Grieskirchen, Institut für Hygiene und Mikrobiologie Wels
Austria AKH Wien, Universitätsklinik für Innere Medizin 1 Wien
Germany Universitätsmedizin Charité Berlin
Germany Vivantes Kliniken Neukölln Berlin
Germany Städtisches Klinikum Braunschweig Braunschweig
Germany Universitäts Düsseldorf; Klinik für Anästhesiologie Dusseldorf
Germany Universitätsklinikum Frankfurt Frankfurt
Germany Universität Hamburg-Eppendorf Hamburg
Germany Universitätsklinikum Jena; Zentrum für Infektionsmedizin Jena
Germany Universitätsklinikum Schleswig-Holstein Kiel
Germany Universitätsklinik Schleswig-Holstein Lübeck
Germany LMU München München
Germany Universitätsklinikum Münster Münster
Germany Klinikum Oldenburg Oldenburg in Holstein
Germany Universitätsklinik Regensburg; Klinik für Anästhesiologie Regensburg
Germany Kliniken Nordoberpfalz Weiden
Greece RIO Univ. Hospital, Dept of Pathology, Division of Infectious Diseases Patras
Italy Clinical Malattie Infettive Bari
Italy Azienda Ospedaliera S.Croce e Carle Cuneo
Italy Ospedal Policlinico San Martino Genova
Italy Ospedale L. Sacco Mailand
Italy Istituto Mediterraneo per i Trapianti Ismett IRCCS Palermo
Italy Policlinico Paolo Giaccone Palermo
Italy Lazzaro Spallanzani Rom
Italy Policlinico Umberto I, Malattie Infettive Rom
Italy Polocinico Tor Vergata Rom
Italy AOU Città della Salute e Scienza-Presidio Molinette Torino
Italy Ospedale S.M.della Misericordia Udine
Italy ASST-Sette Lagh Viale Borre Varese
United Kingdom Royal Bolton Hospital Bolton
United Kingdom Hull & East Yorkshire Hospitals NHS Trust Cottingham
United Kingdom Ninewells Hospital Dundee
United Kingdom Queen Elisabeth University Hospital Glasgow
United Kingdom University of Glasgow/Royal Infirmary Glasgow
United Kingdom University Hospital Crosshouse Kilmarnock
United Kingdom Chelsea & Westminster Hospial London
United Kingdom Queen Elisabeth Hospital London
United Kingdom Univresity College Londen (UCL) Hospital London

Sponsors (3)

Lead Sponsor Collaborator
Infectopharm Arzneimittel GmbH Dr. Oestreich + Partner GmbH, INPADS GmbH

Countries where clinical trial is conducted

Austria,  Germany,  Greece,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with clinical success as defined as clinical cure or clinical improvement Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase).
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment)
Secondary Microbiological cure Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment.
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment)
Secondary Microbiological cure Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase).
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment)
Secondary Microbiological cure Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient.
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment)
Secondary Microbiological cure Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse.
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis")
Secondary Clinical success as defined as clinical cure or clinical improvement Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment.
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment)
Secondary Clinical success as defined as clinical cure or clinical improvement Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient.
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment)
Secondary Clinical success as defined as clinical cure or clinical improvement Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse.
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis")
Secondary Clinical cure Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase).
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment)
Secondary Clinical cure Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient.
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment)
Secondary Clinical cure Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse.
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis")
Secondary Clinical improvement Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment.
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment)
Secondary Clinical improvement Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase).
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment)
Secondary Clinical improvement Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient.
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment)
Secondary Clinical improvement Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and
microbiological cure or no additional antibiotic therapy for the targeted infection necessary.
Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or
in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered.
Time Frame:
Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse.
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis")
Secondary Sodium serum levels On every day from start of fosfomycin treatment until end of hospital stay (up to 6 months after start of fosfomycin treatment)
Secondary Potassium serum levels On every day from start of fosfomycin treatment until end of hospital stay (up to 6 months after start of fosfomycin treatment)
Secondary Adverse events On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Non-serious adverse events On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Serious adverse events On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Cases of death On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Adverse drug reactions (ADRs) On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Serious adverse drug reactions (SADRs) On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
Secondary Dropouts due to treatment failure or due to adverse events On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3